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Novel CLCN7 compound heterozygous mutations
in intermediate autosomal recessive osteopetrosis
Nana Okamoto1, Tomohiro Kohmoto2, Takuya Naruto2, Kiyoshi Masuda2, Takahide Komori1 and Issei Imoto2
Osteopetrosis is a heritable disorder of the skeleton that is characterized by increased bone density on radiographs caused by
defects in osteoclast formation and function. Mutations in 410 genes are identified as causative for this clinically and genetically
heterogeneous disease in humans. We report two novel missense variations in a compound heterozygous state in the CLCN7 gene,
detected through targeted exome sequencing, in a 15-year-old Japanese female with intermediate autosomal recessive
osteopetrosis.
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Osteopetrosis is a heritable, clinically, and genetically hetero-
geneous group of conditions that share the hallmark, observable
on radiographs, of increased bone density caused by a failure of
osteoclast development or function.1 The Nosology Group of the
International Skeletal Dysplasia Society classifies these osteope-
trotic conditions into several distinct entities based on clinical
features, mode of inheritance, and underlying molecular and
pathogenetic mechanisms.2 Mutations in at least 10 genes have
been identified as causative in humans, accounting for 70% of all
cases.3 These conditions can be inherited as autosomal recessive,
dominant or X-linked traits, with the most severe forms being
autosomal recessive. In addition to the paradigmatic recessive
malignant and dominant benign forms, an intermediate group
exists in which the defect can be inherited as either a recessive or
a dominant trait. These intermediate cases often represent a
diagnostic challenge, although diagnosis is mostly based on
clinical and radiographic evaluation. Genetic testing can be used
to confirm the diagnosis and to differentiate among the different
subtypes of osteopetrosis, to provide additional information
regarding the natural history and to predict likely responses to
specific treatments and recurrence risks for adapted genetic
counseling.1
Here, we present a case of intermediate autosomal recessive
osteopetrosis (IARO; MIM 259710) with novel compound hetero-
zygous mutations of the CLCN7 gene (MIM 602727), detected
using a targeted exome sequencing (TES)-based approach to
differentially cover possible causative genes for osteopetrosis,
although IARO is generally caused by either homozygous/
compound heterozygous mutations of CLCN7 or PLEKHM1.1
A 15-year-old Japanese female was the first child of non-
consanguineous, healthy parents who had no notable family
disease history (Figure 1a). Her first visit to the Department of Oral
and Maxillofacial Surgery of Kobe University Hospital was at the
age of 9 years. She had a history of fracture of the leg at the age of
5 years and was tentatively diagnosed with IARO based on clinical
histories and signs at another hospital. Her early motor milestones
and language development were normal, and she possessed
normal intelligence. The patient presented with spontaneous
fractures in the first years of life and a generalized increase in
bone density. On presentation, her height and weight were
146.7 cm (−2.1 s.d.) and 50 kg (−0.2 s.d.), respectively. Her head
circumference (55.9 cm) did not suggest any abnormality. She had
normal hearing, but she had mild bilateral visual impairment due
to atrophy of the bilateral optic nerves. Asymmetrical deformity of
the fractured leg had not significantly progressed. She had a
heavy malocclusion with hypodontia, several impacted teeth,
enamel dysplasia, and malformed teeth (Figure 1b). Skeletal
radiographs showed a diffuse increase in bone density with
various characteristic signs, such as a ‘sandwich’ appearance in the
vertebrae and a ‘bone-within-bone’ appearance of the iliac wings
(Figure 1c–f). No hepatosplenomegaly was noted during the
physical examination. Blood counts and phosphocalcic parameters
were normal, and her karyotype was normal. No causative
mutations were reported by sequence analyzes of all coding
exons of TCIRG1 and CLCN7 performed at another hospital. Her
clinical and radiological features were compatible with those of
IARO, but the patient remained molecularly undiagnosed.
After informed consent was obtained from the patient’s
parents, molecular diagnosis was performed on genomic DNA
extracted from a blood sample. The study was approved by the
Ethics Committees of Kobe University and Tokushima University.
To simultaneously screen multiple osteopetrosis-causing genes,
we first performed TES for the proband using a TruSight One
Sequencing Panel (Illumina, San Diego, CA, USA), which allows the
targeted sequencing of the exon regions of 4813 clinically relevant
genes, and a MiSeq sequencer (Illumina) with our pipeline for next
generation sequencing data analysis, as described elsewhere,4,5
with a minor modification due to a software update specific for a
bioinformatics pipeline.6 To identify presumably pathogenic
single-nucleotide variants, we excluded minor sequence variants
with relatively high-allele frequencies, i.e., 40.01, included in the
1000 Genomes Project database (http://www.1000genomes.org/),
the NHLBI GO Exome Sequencing Project (ESP6500, http://evs.gs.
washington.edu/EVS/), the Human Genetic Variation Database
(HGVD, http://www.genome.med.kyoto-u.ac.jp/SnpDB/) and the
Integrative Japanese Genome Variation Database (iJGVD, https://
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ijgvd.megabank.tohoku.ac.jp/). The detection of copy-number
variations (CNV) using TES data with a resolution of a single exon
to several exons, depending on the exon size, was performed as
previously described.6 These analyzes detected two different
single-base substitutions, NM_001287.5(CLCN7_v001):c.1505G4A
and c.1729G4A, in exons 17 and 19, respectively, and the
substitutions in the exons were confirmed by Sanger sequencing
(Figure 2a). The patient’s mother and father were heterozygous
carriers of the c.1505G4A and the c.1729G4A variations,
respectively, suggesting that these variations were present in
the patient in a compound heterozygous state. These variations
transformed the codon for cysteine 502 into that for tyrosine
[NM_001287.5(CLCN7_i001):p.(Cys502Tyr)] and the codon for
valine 577 into that for methionine [p.(Val577Met)], respectively.
These variants are not present in the Human Gene Mutation
Database (HGMD, Professional 2017.1, http://www.hgmd.org/) or
ClinVar (http://www.ncbi.nlm.nih.gov/clinvar/). No cases with p.
(Cys502Tyr) are present in the publicly available variation
databases, whereas one heterozygous case (carrier) with p.
(Val577Met) was found in the Exome Aggregation Consortium
(ExAC, http://exac.broadinstitute.org/) database. In multiple bioin-
formatics tools, including MutationTaster (http://www.mutationta
ster.org/index.html), PolyPhen-2 version 2.2.2r405 (http://genetics.
bwh.harvard.edu/pph2/index.shtml) and PROVEAN (http://pro
vean.jcvi.org), p.(Cys502Tyr) was predicted to be deleterious by
all three tools, whereas p.(Val577Met) was predicted to be
deleterious by MutationTaster and Polyphen-2 and to be neutral
by PROVEAN. p.(Cys502Tyr) and p.(Val577Met) are located within
one of the helical transmembrane domains (TMDs) and within the
loop between two TMDs, respectively. Multiple sequence align-
ment of CLCN7 orthologous proteins from different metazoan
species revealed that these missense variants affected highly
conserved residues (Figure 2b). No possible disease-causing
variants, including CNVs, were detected within the potential
candidate genes causing osteopetrosis in the TruSight One
Sequencing Panel. As a result of the molecular diagnosis and re-
evaluation of the clinical features of the affected patient and her
unaffected parents having one of the mutations, the patient
presented here was diagnosed with IARO caused by novel
pathogenic missense mutations of CLCN7 in a compound
heterozygous state. Because no possible features associated with
osteopetrosis were observed in the patient’s sister, her allele
status as a potential carrier was not determined through testing.
Mutations in the CLCN7 gene encoding the chloride channel of
the osteoclast membrane are associated with 75% of autosomal
dominant osteopetrosis (ADO) cases, 10–15% of autosomal
recessive osteopetrosis (ARO) cases and all cases of the
intermediate form.7 Mutations in the CLCN7 gene affect the
function of osteoclast-mediated extracellular acidification, result-
ing in the disturbed dissolution of the bone inorganic matrix and a
Figure 1. (a) Family pedigree; arrow shows the proband (P). (b) Orthopantomography showing impacted teeth, enamel hypoplasia and
malformed premolars and roots. (c) Lateral radiograph of the skull showing diffuse thickening of the calvarium. (d) Lateral radiograph of the
spine showing a ‘sandwich’ vertebrae appearance (arrows). (e) Radiograph of the lower limb and pelvis showing diffuse thickening of bones,
with a ‘bone-within-bone’ appearance (arrows). (f) Radiograph of hands showing the ‘bone-within-bone’ appearance in metacarpals (arrows)
and phalanges.
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series of clinical features.8 One of the mutations, p.(Val577Met),
observed in the present case, was predicted to be a ‘neutral’
change by one of the three bioinformatics tools used in this study.
With regard to the findings that the complete loss of function of
the CLCN7 chloride channel causes malignant ARO, whereas
dominant negative missense CLCN7 mutations are responsible for
ADO,9 this result supports the hypothesis that the intermediate
phenotype observed in IARO results from CLCN7 mutations that
only mildly reduce the capacity of Cl− conductance.10 As noted by
Pang et al.,11 a genetic analysis with prediction software would be
insufficient to fully predict the functions of novel mutations in
IARO due to the relatively small number of IARO cases and the
possible partial residual capacity of Cl− conductance associated
with mutated CLCN7 proteins in IARO. Our case contributes to
enriching the database of CLCN7 mutations and improves our
understanding of the clinical and biological aspects of IARO.
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Figure 2. (a) Partial sequence chromatograms of exons 17 and 19 of CLCN7 in a patient and both parents. The nucleotide and corresponding
amino acid sequences of the wild-type and mutant CLCN7 genes are also shown. (b) Multiple amino acid sequence alignment of the CLCN7
orthologous proteins from different metazoan species around the mutated amino acid. Arrowheads denote the mutated amino acid. Amino
acids matching those in Homo sapiens are shaded.
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